Viatris: Mylan No Longer Subject of Antitrust Investigation by Justice Dept
By Chris Wack
Viatris said the Antitrust Division of the U.S. Department of Justice has advised that it no longer considers Mylan, and its former president, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry.
In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris.
The Civil Division of the DOJ has also informed the company that it doesn't expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
Viatras said this outcome affirms its position that Mylan investigated these allegations thoroughly and found no evidence of wrongdoing on the part of Mylan or its employees.
The company said it will continue to defend itself against the remaining civil lawsuits pertaining to these matters.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 02, 2024 08:12 ET (12:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks